The published uses in dogs are to prevent post-operative bleeding in greyhounds, who are known to have a higher than normal fibrinolytic activity. Use of EACA in these patients led to fewer and less severe bleeding episodes (Marin JVECC 2012 , Marin Vet Surg 2012 . A pilot study conducted at Michigan State showed that dogs with immune-mediated thrombocytopenia treated with intravenous EACA infusions had reduced hyperfibrinolysis (compared to placebo). The medication was well-tolerated (Ralph et al. IVECCS proceedings 2013) . Dogs in liver failure have shown an increased incidence of hypercoagulability and hyperfibrinolysis on TEG tracings. This may explain clinically relevant post-liver biopsy bleeding in those patients who have normal PT/PTT levels (Webster C. ACVIM Proceedings 2014). An in-vitro study with injectable EACA given orally in dogs showed that the minimum dose required to improve clot strength and reduce fibrinolysis was 50 mg/kg (Brown et al. ACVS abstract). There is evidence that dogs likely require higher doses than humans to adequately reduce fibrinolysis (Fletcher AJVR 2014) .
Epsilon Aminocaproic Acid Updated September 2016
Dosing Recommendations: Any use of EACA in dogs is considered Off-Label. There are no reports regarding usage in cats.
• For greyhounds undergoing surgery o 500-1000mg PO per dog q8 hours, the night of surgery; continue for 5 days post-op OR o 15-40 mg/kg IV immediately after surgery, then 500-1000mg total PO q8 for 5 days • For dogs with acute hemorrhage suspected to be due to hyperfibrinolysis (severe trauma, uncontrolled bleeding with or without alterations in coagulation profile, thrombocytopenia) o 50-100 mg/kg IV immediately, then 50 mg/kg IV or PO q8 for 5 days • Perioperative management of dogs with liver disease or dysfunction (not published)
o Oral EACA 500-1000mg per dog q8 hours, starting prior to the procedure and continued for 5 days after o 50 mg/kg IV immediately after procedure, then 50 mg/kg IV or PO q8 for 5 days 
